Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of FL-101 in Healthy Subjects
NCT04983732Phase 1Completed
- Sponsor
- Flame Biosciences
- Start
- Sep 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abdakibart in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Flame Biosciences. Primary endpoint: FL-101 Absolute Bioavailability at Day 85. Started Sep 2021; status: completed.
02
Drugs
abdakibart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04983732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983732.